A new trading day began on Tuesday, with CytomX Therapeutics Inc (NASDAQ: CTMX) stock price remained unchanged from the previous day of trading, before settling in for the closing price of $1.21. CTMX’s price has ranged from $1.04 to $5.85 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 28.25% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -3053.00%. With a float of $76.79 million, this company’s outstanding shares have now reached $78.12 million.
In an organization with 122 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.63%, operating margin of 4.79%, and the pretax margin is 12.61%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CytomX Therapeutics Inc is 1.69%, while institutional ownership is 72.25%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of 0.04 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3053.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Here are CytomX Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.14, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.61 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.44 million. That was inferior than the volume of 2.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.44%. Additionally, its Average True Range was 0.07.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 2.52%, which indicates a significant decrease from 50.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.86% in the past 14 days, which was lower than the 223.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2822, while its 200-day Moving Average is $1.6946. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $1.2467. Second resistance stands at $1.2833. The third major resistance level sits at $1.3067. If the price goes on to break the first support level at $1.1867, it is likely to go to the next support level at $1.1633. The third support level lies at $1.1267 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
With a market capitalization of 94.53 million, the company has a total of 77,919K Shares Outstanding. Currently, annual sales are 101,210 K while annual income is -570 K. The company’s previous quarter sales were 25,120 K while its latest quarter income was -6,530 K.
